Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
4.1B CRISPR/Cas9 KO Plasmid (m): sc-420186
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- 4.1B CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the 4.1B genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: 4.1B Antibody (B-6): sc-398089
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
4.1B CRISPR/Cas9 KO Plasmid (m) | sc-420186 | 20 µg | $397.00 |
Overview
Epb41l3 encodes protein 4.1B, a membrane-associated cytoskeletal adaptor that links transmembrane proteins to the cortical actin–spectrin network and helps organize cell shape, polarity, and adhesion. In mouse tissues, 4.1B contributes to membrane stability and junctional architecture, influencing processes such as neurite outgrowth, cell migration, and contact-dependent signaling. Through its scaffolding functions, 4.1B can modulate receptor and adhesion molecule distribution, impacting cytoskeletal remodeling pathways and mechanotransduction. Altered EPB41L3/4.1B regulation has been associated with disrupted tissue organization and phenotypes relevant to tumor suppression, invasion, and neurological homeostasis in experimental models.
4.1B CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Epb41l3 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Epb41l3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Epb41l3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish 4.1B protein expression.
This CRISPR knockout system enables efficient generation of Epb41l3-deficient cell models for investigation of 4.1B signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Epb41l3 exon(s) critical for 4.1B function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Epb41l3 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by 4.1B CRISPR/Cas9 KO Plasmid (m) and 4.1B CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Epb41l3 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by 4.1B HDR Plasmid (m) and 4.1B HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Epb41l3 homology arms to support homology-directed repair at defined Epb41l3 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.